Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 2 4Phase 1/2 3Phase EARLY_PHASE1 1

Status

Terminated 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 1Lymphoid 1

Conditions

Neoplasms 2Advanced Solid Tumors 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × urelumab × Clear all
NCT02253992 2020-10-05

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Bristol-Myers Squibb

Phase 1/2 Terminated
232 enrolled 17 charts
LymphoidOther solid neoplasm

Advanced Solid Tumors

NCT03792724 2019-01-03

INTRUST

Clinica Universidad de Navarra, Universidad de Navarra

Phase 1/2 Unknown
32 enrolled
Tumor-Agnostic

Neoplasms

NCT00309023 2015-10-12

Study of BMS-663513 in Patients With Advanced Cancer

Bristol-Myers Squibb

Phase 1/2 Terminated
115 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡